Merck (MRK) Tops Q2 EPS by 12c, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Merck (MRK) tops earnings, revenue expectations but guidance mixed
July 30, 2024 6:49 AM EDT(Updated - July 30, 2024 10:02 AM EDT)
Merck (NYSE: MRK) reported a robust second quarter, with adjusted earnings per share (EPS) of $2.28, surpassing analysts' predictions by $0.12. The pharmaceutical giant also exceeded revenue expectations, posting $16.11 billion against a $15.85 billion consensus.
However, the company's stock has fallen by more than 6% following the report.
The company's chairman and CEO, Robert Davis, attributed the strong quarterly performance to "excellent scientific, commercial and operational execution," highlighting the successful U.S. launch of WINREVAIR and positive European opinions for adults with pulmonary... More
